Evaluation of serum Fibroblast growth factor-23 in patients with beta-thalassemia major compared to healthy population

Evaluation of serum Fibroblast growth factor-23 in patients with beta-thalassemia major compared to healthy population

Background: The role of phosphate hemostasis in development of thalassemia bone disease has not been extensively studied yet. Due to the lack of sufficient human studies about the changes of serum Fibroblast growth factor-23(FGF23) in patients with beta-thalassemia major as the first step of investi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Iranian journal of pediatric hematology and oncology 2022-07
Hauptverfasser: Saki, Forough, Ranjbar Omrani, Gholamhossein
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Iranian journal of pediatric hematology and oncology
container_volume
creator Saki, Forough
Ranjbar Omrani, Gholamhossein
description Background: The role of phosphate hemostasis in development of thalassemia bone disease has not been extensively studied yet. Due to the lack of sufficient human studies about the changes of serum Fibroblast growth factor-23(FGF23) in patients with beta-thalassemia major as the first step of investigating the role of FGF23 in thalassemia bone disease, the present study aimed to investigate the serum level of FGF23 in patients with thalassemia major. Material and Method: In this case-control study, 25 patients with beta thalassemia major and their age- and sex-matched healthy volunteers were enrolled. Serum phosphorous, calcium, parathyroid hormone (PTH), 25(OH) D, erythropoietin (EPO), serum intact FGF23 (iFGF23) and 1,25 (OH)2 D were checked and analyzed. Result: Patients with beta-thalassemia major had lower 1,25 (OH)2D, (p = 0.025), higher phosphate (p = 0.002), and higher PTH (P
doi_str_mv 10.18502/ijpho.v12i3.10061
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_18502_ijpho_v12i3_10061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_18502_ijpho_v12i3_10061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c128t-658cd50e4ff778b6d8fd8bd2c266dc13d116a28b183e7cd2235f2fbb7a474ca3</originalsourceid><addsrcrecordid>eNpNkMtqwzAQRUVpoSHND3SlH7Crhy2ryxKSthDoJnszetUKtmUkJSF_X-N20buZC3OYgYPQMyUllTVhL_40daG8UOZ5SQkR9A6tGCGykPKV3f_rj2iT0onMEYTWpFqhy-4C_RmyDyMODicbzwPeexWD6iFl_B3DNXfYgc4hFoxjP-Jpxu2YE776eaVshiJ3MOPJDh7wAKcQsQ7DBNEanAPuLPS5u-EpTOd--fWEHhz0yW7-5hod97vj9qM4fL1_bt8OhaZM5kLUUpua2Mq5ppFKGOmMVIZpJoTRlBtKBTCpqOS20YYxXjvmlGqgaioNfI3Y71kdQ0rRunaKfoB4aylpF3ft4q5d3LWLO_4DxkNnTA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Evaluation of serum Fibroblast growth factor-23 in patients with beta-thalassemia major compared to healthy population</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Saki, Forough ; Ranjbar Omrani, Gholamhossein</creator><creatorcontrib>Saki, Forough ; Ranjbar Omrani, Gholamhossein</creatorcontrib><description>Background: The role of phosphate hemostasis in development of thalassemia bone disease has not been extensively studied yet. Due to the lack of sufficient human studies about the changes of serum Fibroblast growth factor-23(FGF23) in patients with beta-thalassemia major as the first step of investigating the role of FGF23 in thalassemia bone disease, the present study aimed to investigate the serum level of FGF23 in patients with thalassemia major. Material and Method: In this case-control study, 25 patients with beta thalassemia major and their age- and sex-matched healthy volunteers were enrolled. Serum phosphorous, calcium, parathyroid hormone (PTH), 25(OH) D, erythropoietin (EPO), serum intact FGF23 (iFGF23) and 1,25 (OH)2 D were checked and analyzed. Result: Patients with beta-thalassemia major had lower 1,25 (OH)2D, (p = 0.025), higher phosphate (p = 0.002), and higher PTH (P &lt;0.001) compared to the control group; however, all of them were in their normal blood range. They also had higher serum FGF23 (p = 0.007) and higher EPO (P&lt;0.001). Serum FGF23 had an independent association with serum Iron (p=0.016), 1, 25(OH)2 Vitamin D (p&lt;0.001), and hemoglobin (p=0.002). Conclusion: Serum FGF23 was associated with serum Iron, 1, 25(OH)2 Vitamin D, and hemoglobin in beta-thalassemia major patients. Hence, it seems that regular transfusions and chelating agents which can decrease the serum iron and increase hemoglobin level can be associated with lower iFGF23.</description><identifier>ISSN: 2008-8892</identifier><identifier>EISSN: 2008-8892</identifier><identifier>DOI: 10.18502/ijpho.v12i3.10061</identifier><language>eng</language><ispartof>Iranian journal of pediatric hematology and oncology, 2022-07</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Saki, Forough</creatorcontrib><creatorcontrib>Ranjbar Omrani, Gholamhossein</creatorcontrib><title>Evaluation of serum Fibroblast growth factor-23 in patients with beta-thalassemia major compared to healthy population</title><title>Iranian journal of pediatric hematology and oncology</title><description>Background: The role of phosphate hemostasis in development of thalassemia bone disease has not been extensively studied yet. Due to the lack of sufficient human studies about the changes of serum Fibroblast growth factor-23(FGF23) in patients with beta-thalassemia major as the first step of investigating the role of FGF23 in thalassemia bone disease, the present study aimed to investigate the serum level of FGF23 in patients with thalassemia major. Material and Method: In this case-control study, 25 patients with beta thalassemia major and their age- and sex-matched healthy volunteers were enrolled. Serum phosphorous, calcium, parathyroid hormone (PTH), 25(OH) D, erythropoietin (EPO), serum intact FGF23 (iFGF23) and 1,25 (OH)2 D were checked and analyzed. Result: Patients with beta-thalassemia major had lower 1,25 (OH)2D, (p = 0.025), higher phosphate (p = 0.002), and higher PTH (P &lt;0.001) compared to the control group; however, all of them were in their normal blood range. They also had higher serum FGF23 (p = 0.007) and higher EPO (P&lt;0.001). Serum FGF23 had an independent association with serum Iron (p=0.016), 1, 25(OH)2 Vitamin D (p&lt;0.001), and hemoglobin (p=0.002). Conclusion: Serum FGF23 was associated with serum Iron, 1, 25(OH)2 Vitamin D, and hemoglobin in beta-thalassemia major patients. Hence, it seems that regular transfusions and chelating agents which can decrease the serum iron and increase hemoglobin level can be associated with lower iFGF23.</description><issn>2008-8892</issn><issn>2008-8892</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpNkMtqwzAQRUVpoSHND3SlH7Crhy2ryxKSthDoJnszetUKtmUkJSF_X-N20buZC3OYgYPQMyUllTVhL_40daG8UOZ5SQkR9A6tGCGykPKV3f_rj2iT0onMEYTWpFqhy-4C_RmyDyMODicbzwPeexWD6iFl_B3DNXfYgc4hFoxjP-Jpxu2YE776eaVshiJ3MOPJDh7wAKcQsQ7DBNEanAPuLPS5u-EpTOd--fWEHhz0yW7-5hod97vj9qM4fL1_bt8OhaZM5kLUUpua2Mq5ppFKGOmMVIZpJoTRlBtKBTCpqOS20YYxXjvmlGqgaioNfI3Y71kdQ0rRunaKfoB4aylpF3ft4q5d3LWLO_4DxkNnTA</recordid><startdate>20220716</startdate><enddate>20220716</enddate><creator>Saki, Forough</creator><creator>Ranjbar Omrani, Gholamhossein</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20220716</creationdate><title>Evaluation of serum Fibroblast growth factor-23 in patients with beta-thalassemia major compared to healthy population</title><author>Saki, Forough ; Ranjbar Omrani, Gholamhossein</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c128t-658cd50e4ff778b6d8fd8bd2c266dc13d116a28b183e7cd2235f2fbb7a474ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Saki, Forough</creatorcontrib><creatorcontrib>Ranjbar Omrani, Gholamhossein</creatorcontrib><collection>CrossRef</collection><jtitle>Iranian journal of pediatric hematology and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saki, Forough</au><au>Ranjbar Omrani, Gholamhossein</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of serum Fibroblast growth factor-23 in patients with beta-thalassemia major compared to healthy population</atitle><jtitle>Iranian journal of pediatric hematology and oncology</jtitle><date>2022-07-16</date><risdate>2022</risdate><issn>2008-8892</issn><eissn>2008-8892</eissn><abstract>Background: The role of phosphate hemostasis in development of thalassemia bone disease has not been extensively studied yet. Due to the lack of sufficient human studies about the changes of serum Fibroblast growth factor-23(FGF23) in patients with beta-thalassemia major as the first step of investigating the role of FGF23 in thalassemia bone disease, the present study aimed to investigate the serum level of FGF23 in patients with thalassemia major. Material and Method: In this case-control study, 25 patients with beta thalassemia major and their age- and sex-matched healthy volunteers were enrolled. Serum phosphorous, calcium, parathyroid hormone (PTH), 25(OH) D, erythropoietin (EPO), serum intact FGF23 (iFGF23) and 1,25 (OH)2 D were checked and analyzed. Result: Patients with beta-thalassemia major had lower 1,25 (OH)2D, (p = 0.025), higher phosphate (p = 0.002), and higher PTH (P &lt;0.001) compared to the control group; however, all of them were in their normal blood range. They also had higher serum FGF23 (p = 0.007) and higher EPO (P&lt;0.001). Serum FGF23 had an independent association with serum Iron (p=0.016), 1, 25(OH)2 Vitamin D (p&lt;0.001), and hemoglobin (p=0.002). Conclusion: Serum FGF23 was associated with serum Iron, 1, 25(OH)2 Vitamin D, and hemoglobin in beta-thalassemia major patients. Hence, it seems that regular transfusions and chelating agents which can decrease the serum iron and increase hemoglobin level can be associated with lower iFGF23.</abstract><doi>10.18502/ijpho.v12i3.10061</doi></addata></record>
fulltext fulltext
identifier ISSN: 2008-8892
ispartof Iranian journal of pediatric hematology and oncology, 2022-07
issn 2008-8892
2008-8892
language eng
recordid cdi_crossref_primary_10_18502_ijpho_v12i3_10061
source EZB-FREE-00999 freely available EZB journals
title Evaluation of serum Fibroblast growth factor-23 in patients with beta-thalassemia major compared to healthy population
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T01%3A51%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20serum%20Fibroblast%20growth%20factor-23%20in%20patients%20with%20beta-thalassemia%20major%20compared%20to%20healthy%20population&rft.jtitle=Iranian%20journal%20of%20pediatric%20hematology%20and%20oncology&rft.au=Saki,%20Forough&rft.date=2022-07-16&rft.issn=2008-8892&rft.eissn=2008-8892&rft_id=info:doi/10.18502/ijpho.v12i3.10061&rft_dat=%3Ccrossref%3E10_18502_ijpho_v12i3_10061%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true